Literature DB >> 26592830

Reduced expression of miR-503 is associated with poor prognosis in cervical cancer.

Z-L Yin1, Y-L Wang, S-F Ge, T-T Guo, L Wang, X-M Zheng, J Liu.   

Abstract

OBJECTIVE: We wished to evaluate the association between expression of microRNA (miR) -503 and prognosis in patients with cervical cancer. PATIENTS AND METHODS: 96 paired specimens of cervical cancer and adjacent normal cervical epithelial tissues were obtained. qPCR was used to evaluate expression levels of miR-503. We analyzed the associations between miR-503 expression levels and clinicopathological parameters, as well as recurrence-free and overall survival with Kaplan-Meier survival curves and proportional hazards model.
RESULTS: miR-503 levels were significantly (p < 0.001) lower in cervical cancer tissue compared with adjacent normal cervical epithelial tissue. We further observed significant associations of expression of this miR and recurrence of cervical cancer, lymph node metastasization, and International Federation of Gynecology and Obstetrics (FIGO) stage. In addition, in multivariate analysis, miR-503 expression level was found to be an independent prognostic factor for both recurrence-free and overall survival.
CONCLUSIONS: Reduced expression of miR-503 is an independent prognostic factor in cervical cancer indicating poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26592830

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  15 in total

1.  MicroRNA-503 serves an oncogenic role in retinoblastoma progression by directly targeting PTPN12.

Authors:  Yang Cheng; Wei Liu
Journal:  Exp Ther Med       Date:  2019-07-19       Impact factor: 2.447

2.  Role of microRNAs in Predicting the Prognosis of Cervical Cancer Cases: A Systematic Review and Meta-Analysis.

Authors:  Sasidharanpillai Sabeena; Nagaraja Ravishankar
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

3.  An integrative transcriptomics approach identifies miR-503 as a candidate master regulator of the estrogen response in MCF-7 breast cancer cells.

Authors:  Jeanette Baran-Gale; Jeremy E Purvis; Praveen Sethupathy
Journal:  RNA       Date:  2016-08-18       Impact factor: 4.942

4.  A three miRNAs signature predicts survival in cervical cancer using bioinformatics analysis.

Authors:  Bin Liang; Yunhui Li; Tianjiao Wang
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

5.  Expression patterns of microRNA-329 and its clinical performance in diagnosis and prognosis of breast cancer.

Authors:  Pihong Li; Jianda Dong; Xiang Zhou; Weijian Sun; He Huang; Tong Chen; Bing Ye; Zhiqiang Zheng; Mingdong Lu
Journal:  Onco Targets Ther       Date:  2017-11-28       Impact factor: 4.147

6.  Hepatitis C Virus Nonstructural 5A Protein (HCV-NS5A) Inhibits Hepatocyte Apoptosis through the NF-κb/miR-503/bcl-2 Pathway.

Authors:  Zhengyuan Xie; Zhihua Xiao; Fenfen Wang
Journal:  Mol Cells       Date:  2017-03-27       Impact factor: 5.034

7.  MicroRNA‑503 serves an oncogenic role in laryngeal squamous cell carcinoma via targeting programmed cell death protein 4.

Authors:  Yu Shuang; Xuan Zhou; Chao Li; Yongwang Huang; Lun Zhang
Journal:  Mol Med Rep       Date:  2017-08-17       Impact factor: 2.952

8.  MiR-375 Is Epigenetically Downregulated by HPV-16 E6 Mediated DNMT1 Upregulation and Modulates EMT of Cervical Cancer Cells by Suppressing lncRNA MALAT1.

Authors:  Shikai Liu; Lili Song; Hairong Yao; Liang Zhang; Dongkui Xu; Fangyuan Gao; Qian Li
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

9.  MiR-503 modulates epithelial-mesenchymal transition in silica-induced pulmonary fibrosis by targeting PI3K p85 and is sponged by lncRNA MALAT1.

Authors:  Weiwen Yan; Qiuyun Wu; Wenxi Yao; Yan Li; Yi Liu; Jiali Yuan; Ruhui Han; Jingjin Yang; Xiaoming Ji; Chunhui Ni
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

10.  Correlation between miR-222 and uterine cancer and its prognostic value.

Authors:  Xiujuan Nie; Haili Tian
Journal:  Oncol Lett       Date:  2018-05-25       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.